At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
Rozanolixizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
In Brief
A Phase 2 clinical trial evaluating Rozanolixizumab for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Completed, enrolled 21 participants across 14 sites in 8 countries.
Detailed Summary
The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Denmark, France, Germany, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartAug 2019
Primary CompletionNov 2021
TodayJul 2026
First PostedAug 9, 2019
Enrollment StartAug 21, 2019
Primary CompletionNov 10, 2021
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 6.9 years ago
Interventions
Rozanolixizumabdrug
Subjects will receive rozanolixizumab in a specified sequence during the treatment period.